DRG Epidemiology’s coverage of prostate cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of prostate cancer for each country, as well as annualized case counts projected to the national population.

Most patient populations in the major mature pharmaceutical markets are forecast over a period of 20 years; we forecast patient populations in other countries over a 10-year period. In addition to forecasting incident and prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy.

DRG Epidemiology’s prostate cancer forecast will answer the following questions:

  • How will changes in the levels of exposure to known risk or protective factors affect the number of people diagnosed with prostate cancer per year?
  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with prostate cancer per year?
  • How will improvements in survival change the number of people living with a diagnosis of prostate cancer?
  • How will the declining risk of recurrence change the number of people diagnosed with prostate cancer per year?
  • Of all people with prostate cancer, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
  • Of all people diagnosed with prostate cancer, how many in each of the major mature pharmaceutical markets are drug-treated?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the countries considered in this report. These patient flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

DRG Epidemiology provides at least ten years of forecast data for the following prostate cancer patient populations:

  • Diagnosed incident cases by TNM and risk category.
  • Diagnosed prevalent cases by drug-treatment potential.
  • Drug-treatable prevalent cases by metastasis status.
  • Incident cases of biochemically recurrent prostate cancer.
  • Newly diagnosed low/intermediate risk (hormone-sensitive) drug-treatable population.
  • Newly diagnosed high/very high risk (hormone-sensitive) drug-treatable population .
  • Drug-treatment opportunities in biochemically recurrent (hormone-sensitive) prostate cancer.
  • Nonmetastatic castrate-resistant prostate cancer drug-treatable population.
  • First-line MCRPC drug-treatable population.
  • Second-line MCRPCdrug-treatable population .

… and many more (details available on request).

Note: Coverage may vary by country and region.

Table of contents

  • Prostate Cancer - Epidemiology - Mature Markets Data
    • Introduction
      • Key Findings
        • Key Updates
      • Overview
        • Diagnosed Incidence of Prostate Cancer per Year per 100,000 Males of All Ages in 2020 and 2040
        • Relative Sizes of the Contributing Factors to the Trend in Diagnosed Incident Cases of Prostate Cancer over the Next 20 Years
        • Diagnosed Incident Cases of Prostate Cancer in 2020 by TNM Stage Distribution/Risk Grouping
    • Epidemiology Data
    • Methods
      • Diagnosed Incident Cases
      • TNM Stage and NCCN Risk Categories of Prostate Cancer
      • Recurrent Incident Cases of Prostate Cancer
      • Diagnosed Prevalent Cases
      • Drug-Treatable Populations
      • Drug-Treated Populations
      • Lifetime DALYs Gained
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Prostate Cancer
        • Studies Excluded from the Analysis of Prostate Cancer
      • Risk/Protective Factors
        • Risk/Protective Factors for Prostate Cancer
      • Bibliography
      • Glossary

Author(s): Narendra Parihar; Nishant Kumar, M.P.H.

Narendra is an associate epidemiologist within the epidemiology team at Decision Resources Group. Narendra specializes in developing epidemiological forecasts for multiple indications within the DRG syndicated portfolio.

His qualifications include an MPH with specialization in Health Policy, Economics and Finance from the Tata Institute of Social Sciences, Mumbai, and a Bachelor’s degree in Dentistry from the Rajasthan University of Health Sciences.

Nishant Kumar, M.P.H., is an associate director on the Epidemiology team at DRG, part of Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Prior to joining DRG, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.


Related Reports

Prostate Cancer - Landscape & Forecast - Disease Landscape & Forecast

Prostate cancer is the most common cancer among men in developed countries. Hormonal agents are the mainstay of treatment for prostate cancer and are routinely used across lines. Zytiga (Johnson &a...

View Details

Prostate Cancer - Geographic Focus: China - Prostate Cancer - China In-Depth (China)

Prostate cancer is the most common male urinary tumor and sixth most common male malignant tumor in China. Improved screening tools will result in a significant increase in the diagnosed incidence...

View Details

Prostate Cancer - Unmet Need - Detailed, Expanded Analysis - Metastatic Hormone Sensititve

The treatment of newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) has evolved in recent years with the approval...

View Details